Cancer Liquid Biopsy Developer Thrive Launches with $110M in Series A Financing
A liquid biopsy developer focused on commercializing a test developed at Johns Hopkins University to detect multiple cancers at earlier stages has launched with $110 million in Series A financing.
Thrive Earlier Detection aims to develop and commercialize CancerSEEK, a DNA- and protein-based liquid biopsy. The test is designed to detect cancer by analyzing eight tumor specific genomic mutations in circulating tumor DNA (ctDNA) and cancer-associated protein biomarkers in plasma to identify abnormalities that are common across multiple cancers…
I have no position in GH because the valuation suggests that it’s all about the future and the winner(s) in this space have not yet been determined.